Last updated on May 2019

Study of VIR-2218 in Healthy Volunteers and Patients With Chronic Hepatitis B

Brief description of study

This is a phase 1/2 study in which healthy volunteers and subjects with chronic HBV infection will receive VIR-2218 or placebo and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity (only in subjects with chronic HBV).

Clinical Study Identifier: NCT03672188

Find a site near you

Start Over

Investigative Site

Fitzroy, Australia
  Connect »